| Authors: |
Soares M; Centre for Health Economics, University of York, York, England, UK., Colson A; Department of Management Science, University of Strathclyde, Glasgow, Scotland, UK., Bojke L; Centre for Health Economics, University of York, York, England, UK., Ghabri S; Department of Medical Evaluation, HAS, Paris, France., Garay OU; Roche Diagnostics International AG, Rotkreuz, Switzerland., Felli JK; Eli Lilly and Company, Indianapolis, IN, USA., Lee K; Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada., Molsen-David E; ISPOR-Professional Society for Health Economics and Outcomes Research, Lawrenceville, NJ, USA., Morales-Napoles O; Delft University of Technology, Delft, The Netherlands., Shaffer VA; Department of Psychological Sciences, University of Missouri, Columbia, MO, USA., IJzerman MJ; University of Melbourne, School of Population and Global Health, Parkville, Australia; Erasmus School of Health Policy & Management, Rotterdam, The Netherlands. Electronic address: ijzerman@eshpm.eur.nl. |
